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Abstract
Background: Polycystic ovary syndrome (PCOS) is a prevalent women’s health condition with reproductive,
metabolic, and psychological manifestations. Weight loss can improve these symptoms and is a key goal; however,
many women find this difficult to achieve. Acupuncture is a Chinese medical treatment that involves insertion of
very fine metal needles into specific areas of the body and has been shown to be efficacious for weight loss in
non-PCOS populations. However, few studies have been conducted in women with PCOS. A variant of
acupuncture, auricular electro-acupuncture (AEA), may have beneficial effects on sympathetic tone, which is
associated with insulin resistance, obesity and PCOS.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: c.ee@westernsydney.edu.au
ˆNigel Stepto is deceased.
1NICM Health Research Institute, Western Sydney University, Penrith, NSW
2751, Australia
Full list of author information is available at the end of the article
Ee et al. Pilot and Feasibility Studies            (2020) 6:53 
https://doi.org/10.1186/s40814-020-00591-4
(Continued from previous page)
Methods: This prospective three-arm open label parallel randomised controlled trial will assess feasibility and
acceptability of acupuncture and/or AEA for weight loss in women with PCOS. We will enrol 39 women from the
community aged between 18 and 45 years, with physician diagnosis of PCOS according to the Rotterdam criteria:
body mass index (BMI) between 25 and 40 kg/m2. Women will be randomly allocated to receive one of three
treatments for 12 weeks duration: body electro-acupuncture + lifestyle interventions, AEA + lifestyle interventions, or
lifestyle interventions alone. The lifestyle intervention in this study is telephone-based health coaching (between 4
and 13 phone calls, depending on individual need), provided by the Get Healthy Service. Primary outcomes of the
study are feasibility and acceptability of trial methods as determined by recruitment and retention rates, adherence,
acceptability, credibility, and safety. Secondary outcomes include anthropometric (body weight, BMI, waist and hip
circumference), metabolic (glucose tolerance and insulin sensitivity obtained from a 2-h 75 g oral glucose tolerance
test with area under the curve insulin calculated using the trapezoid rule), reproductive (androgen levels, menstrual
cyclicity, clinical hyperandrogenism using the Ferriman-Gallwey scoring system), autonomic (heart rate variability,
blood pressure), lifestyle (physical activity levels, diet quality, weight self-efficacy), quality of life, and psychological
(depression and anxiety symptoms, internal health locus of control).
Discussion: This study addresses the feasibility and acceptability of novel interventions to treat overweight/obesity
in PCOS. Study findings have the potential to generate a new understanding of the role of acupuncture and
auricular acupuncture in weight management.
Trial registration: Australian New Zealand Clinical Trial Registry, 8/6/18 ACTRN12618000975291
Keywords: Polycystic ovary syndrome, PCOS, Obesity, Weight management, Acupuncture, Auricular electro-
acupuncture, Heart rate variability, Insulin resistance
Background
Polycystic ovary syndrome (PCOS) affects up to 13% of
women and can have significant reproductive, metabolic,
and psychological manifestations [1, 2]. Women with
PCOS are more likely to be obese/overweight than age-
matched controls, and excess weight worsens the fea-
tures of PCOS [3]. Weight loss is a key goal in PCOS,
and lifestyle management techniques (diet, exercise, and/
or behavioural interventions) targeted at weight loss are
first-line approaches in overweight/obese women as even
modest weight loss improves reproductive and metabolic
outcomes [4]. Current evidence-based guidelines on
PCOS recommend that obese women embark on 3–6
months of lifestyle management for weight loss prior to
considering assisted reproductive technology (ART).
However, adherence is generally low [5, 6], and achiev-
ing adequate weight loss remains a significant challenge
[4, 7].
In non-PCOS populations, acupuncture, in particular
auricular acupuncture and electro-acupuncture, is more
efficacious than sham for reducing body mass index
(BMI) (mean difference [MD] − 0.47 kg/m2) as well as
body fat mass (MD − 0.66 kg), waist circumference (MD
− 2.02 cm) and hip circumference (MD − 2.74 cm) [8].
These effects are mediated through multiple responses
including appetite suppression [9, 10], modulation of
leptin and ghrelin [11–13], and improved insulin sensi-
tivity [14–19]. Further, acupuncture may alleviate co-
morbid anxiety symptoms in people with obesity [11, 20,
21]. Effects also appear to be sustained after end of
treatment [22]. Randomised controlled trials (RCTs)
conducted in China on women with PCOS indicate that
acupuncture and metformin is superior to metformin
alone in women with PCOS for reducing BMI [23]. One
study reported a mean difference of 0.97 kg/m2 (95% CI
1.51, 0.43) for acupuncture and metformin compared to
metformin alone [24].
A range of factors may contribute to increased BMI in
PCOS, including abnormalities in energy homeostasis
[3]. Insulin resistance (IR) has been demonstrated to be
increased in women with PCOS compared to BMI-
matched controls and is exacerbated by increased BMI
[25, 26]. Increased sympathetic tone is an associated fac-
tor of IR [27] and has been identified as a potential
therapeutic target in PCOS [28]. In rats with steroid-
induced PCOS, electro-acupuncture reduces ovarian
sympathetic hyper-innervation, ameliorates IR, and im-
proves oestrous cycling [29]. Electro-acupuncture re-
duced muscle sympathetic nerve activity in PCOS
women in one trial [27]. Our qualitative work indicates
high levels of acceptance of acupuncture as a possible
adjunct to lifestyle interventions for weight loss [30].
A variant of acupuncture is auricular electro-
acupuncture (AEA). Evidence suggests that AEA stimu-
lates the auricular branch of the vagus nerve which in-
creases parasympathetic tone [31], deactivates the
sympathetic nervous system [31], and suppresses appe-
tite [9].
Given that acupuncture is a relatively safe treatment
[32–34] with preliminary evidence suggesting it may be
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beneficial for weight loss in PCOS when used as an ad-
junct, rigorous clinical research in this area is warranted.
The primary objective of this study is to assess feasibility
and acceptability of trial procedures for a randomised
controlled trial comparing body acupuncture, AEA, and
lifestyle interventions alone for weight loss in women
with PCOS. Secondary objectives are to [1] determine an
effect size for body electro-acupuncture or AEA and life-
style interventions versus lifestyle interventions alone for
change in body weight for limited efficacy testing and to
inform future sample size calculations and [2] explore
the impact of body electro-acupuncture and auricular
electro-acupuncture on sympathetic tone and insulin re-
sistance. The primary outcome for a subsequent phase
IIb trial will be change in weight in kilogrammes.
Methods/design
This is a prospective three-arm open-label parallel ran-
domised controlled trial taking place over a 12-week
intervention period. Ethics approval was obtained from
the Human Research Ethics Committee, Western Sydney
University, H11973 (27 February 2017). The trial was
prospectively registered on the Australian New Zealand
Clinical Trial Registry, ACTRN12618000975291, on 08
June 2018. The study protocol (version 12, 28 August
19) (see Additional file 1) has been designed according
to the SPIRIT guidelines [35] and Good Clinical Practice
guidelines. The trial commenced recruiting in April
2019 and enrolled the first participant on 27 May 2019.
Recruitment, setting, and informed consent
Women living in Sydney, Australia, will be recruited via
advertising through consumer organisations, social
media, University staff and student networks, and fertil-
ity and specialty PCOS clinics. To reduce selection bias,
we will attempt to recruit from a wide variety of sources
targeting the general population. Screening according to
eligibility criteria is initially done through an online sur-
vey and confirmed at the baseline visit where written in-
formed consent will be provided. Participants attend for
body acupuncture and AEA treatment at private acu-
puncture clinics.
Eligibility criteria
The inclusion criteria are as follows: women who are
aged between 18 and 45, with physician diagnosis of
PCOS within the previous 5 years according to the 2003
Rotterdam Criteria [36]; BMI ≥ 25 kg/m2 and < 40kg/m2;
no diagnosis of other endocrine disorders; not on the
following medications in the 3months preceding enrol-
ment: metformin or other medications affecting insulin
and glucose metabolism, hormonal contraceptives or
hormonal treatments for PCOS/assisted reproductive
techniques including gonadotropins and the oral
contraceptive pill or hormonal intrauterine device,
pharmaceutical or complementary (including nutri-
tional/herbal) treatments for weight loss.
Exclusion criteria include:
 Planning to conceive within the next 3 months;
 Not willing to avoid pregnancy for the duration of
the study;
 Currently pregnant or breastfeeding;
 Less than 6 weeks postpartum;
 Breastfeeding within the previous 6 weeks;
 Needle acupuncture in the previous 3 weeks;
 Unable or unwilling to provide informed consent;
 Anticoagulant use;
 Pacemaker use;
 Immunocompromise; or
 Valvular heart disease.
Randomisation, allocation concealment, and blinding
Women are randomised in a 1:1:1 ratio to receive either
body acupuncture and lifestyle intervention, AEA and
lifestyle intervention, or lifestyle intervention alone. Ran-
domisation was performed in permuted blocks. The ran-
domisation sequence was created using a computer
programme (www.sealedenvelope.com) by a researcher
external to the research team. This researcher will hold
the randomisation sequence and created a series of 39
consecutively numbered sealed opaque envelopes that
contain the ID number and allocation. The research as-
sistant allocates participants by selecting the next con-
secutively number sealed opaque envelope that contains
the allocation. Once the participant has had eligibility
confirmed and has provided written informed consent,
she is enrolled and given the next consecutive random-
isation ID number, and the research assistant will open
the numbered envelope to reveal the allocation. Before
opening the envelope, the research assistant writes the
participant’s name on the envelope and the date and
signs the envelope as a record of randomisation. Investi-
gators (outcome assessors and investigators involved in
statistical analysis) are blinded to treatment allocation,
treating acupuncturists and participants are not.
Treatment schedule
Body acupuncture
Chinese medicine needle acupuncture will be delivered
in a semi-pragmatic setting, for a total of 11 treatments
of acupuncture over 12 weeks (twice a week for the first
2 weeks, weekly for 4 weeks, then fortnightly for 3 treat-
ments). A minimum of six study acupuncturists, located
across different areas of metropolitan Sydney, have been
chosen to administer the treatments. They have a bache-
lor’s degree in Chinese Medicine, have five or more
years of clinical experience, and are registered as
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Chinese medicine practitioners (acupuncture) with the
Australian Health Practitioner Regulation Agency
(AHPRA). Study acupuncturists receive hands-on train-
ing from CE, an experienced acupuncture researcher,
and registered acupuncturist. Refresher training is pro-
vided if there has been a break of 2 months or more in
between administering the trial interventions to partici-
pants, and training is complemented by a detailed practi-
tioner manual.
Acupuncturists are to perform Chinese medicine diag-
nosis based on history and examination as per usual
clinical practice. The acupuncture point protocol is a
semi-fixed protocol which delivers a traditionally-based
style of acupuncture where treatment is designed on the
basis of a traditional Chinese Medicine clinical assess-
ment. In choosing the acupuncture prescription, study
acupuncturists are given the following instructions:
 Treatment of obesity/overweight is the primary
objective of the acupuncture treatment
 At least six acupuncture points must be chosen
from a list of 17 core acupuncture points that will
be provided to the practitioner. These points are
chosen from the traditional points that are
recommended for treatment of syndromes that are
related to obesity and PCOS (based on literature and
textbook review) and from the points used in
previous acupuncture for obesity and PCOS trials
[31, 37].
 Points on the chest or back must be avoided to
avoid risk of pneumothorax.
A minimum of ten acupuncture needles will be
inserted per session. The core acupuncture points to be
used are ST36, SP6, ST25, ST40, CV12, CV6, LI11, SP9,
CV9, CV3, CV4, LI4, KI13, KI7, ST28, LR3, and GB34.
Table 1 outlines the location of the points and the Chin-
ese medicine rationale for use of the point [38]. The use
of a manualised semi-fixed protocol, where acupunctur-
ists choose from a core group of acupuncture points ac-
cording to the Chinese medicine diagnosis and follow a
written protocol, ensures that our treatment protocol
maintains fidelity to acupuncture as a medical system
(which requires individualisation and flexibility) while
standardising the treatment that is provided to conform
to scientific research methodology [39, 40].
Acupuncture points will be generally needled bilat-
erally. A combination of manual and electrical stimula-
tion (electro-acupuncture) will be used. De qi, or needle
sensation, is widely considered to be an essential compo-
nent of acupuncture treatment [41] and is defined as
numbness, heaviness, pressure, soreness, or tingling. De qi
will be obtained for each point using thrusting, twirling,
and rotating, until the participant reports numbness,
heaviness, pressure, soreness, or tingling, and needles
are manipulated every 10 min to obtain de qi. Electro-
acupuncture will be applied to ST 28 and SP 6 acupunc-
ture points bilaterally (located on the lower abdomen
and lower leg) and delivered using Therapeutics Goods
Administration (TGA)-approved electro-acupuncture
devices at low frequency (2 Hz) electrical pulses, 0.3 ms
pulse width [42, 43], and continuous stimulation to the
attached needles. The intensity of electro-acupuncture
will be increased gently during each session until muscle
contractions are felt or seen, but below the threshold of
any discomfort or pain. Needles are retained for 30 min.
Acupuncture needles are standard, single use, stainless
steel needles, 0.20 × 30mm. Practitioners will record de-
tails of each diagnosis and treatment, on an individual
case report form which will be kept in a locked cup-
board in the clinic and returned to the research team at
the end of the study.
Auricular electro-acupuncture stimulation
The intervention in this arm is AEA using a fixed proto-
col that is informed by both Chinese medical and med-
ical acupuncture principles based on a literature review
and expert consensus on the traditional and physio-
logical indications of the points. A pilot study suggests
that a novel device, the “NeurovaTM” (NESI Corp), may
be effective for hot flushes from androgen-deprivation
therapy, a condition underpinned by sympathetic hyper-
activity [44]. This method involves insertion of indwell-
ing needles into the concha of the ear and delivery of
intermittent electrical impulses over 96 h by a small
battery-powered device that is worn just below the ear.
This significantly increases the “dose” of acupuncture
that can be delivered (“protracted acupuncture”).
Women allocated to the AEA group will receive a total
of 6 treatments over 12 weeks (once a week for the first
2 weeks, then fortnightly for four treatments), delivered
by study acupuncturists. No additional Chinese medicine
treatments will be provided including body acupuncture,
Chinese herbal medicine, or additional physical or
stimulation treatments such as moxibustion or cupping,
and no Chinese medicine diagnosis is required. There is
to be no variation in treatment. Each subject will receive
needling at three acupuncture points on the concha of
one ear only (stomach, appetite control, and thalamus)
(see Fig. 1).
No de qi sensation is to be sought. The Neuro-
vaTM device will be attached after insertion of the
needles to the ear, according to the manufacturer’s
instructions. Needles are retained for up to 96 h.
The participant is to remove the NeurovaTM device
by gently pulling out the needles and disconnecting
the wire and discarding the device into an approved
sharps disposal container. Participants can remove
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the device before 96 h if they experience significant
discomfort. Needles are surgical-grade titanium, ster-
ile and disposable, and are approximately 6 mm in
length.
Lifestyle interventions only
The Get Healthy Service (GHS) is a free, confidential
telephone-based coaching service that was introduced by
New South Wales (NSW) Ministry of Health in 2009
Table 1 Acupuncture point selection rationale
Acupuncture
point
Relevant Chinese medicine indication(s) for PCOS Location
Zu San Li
(ST36)
Harmonises Stomach, fortifies Spleen and resolves damp, supports
correct Qi original Qi and fosters tonifies Qi and nourishes Blood
and Yin
Below the knee, 3 cuna inferior to Dubi, one finger breadth lateral
to the anterior crest of the tibia
San Yin Jiao
(SP6)
Tonifies Spleen and Stomach Qi and resolves damp, harmonises
Liver and tonifies Kidney regulates menstruation, harmonises
Lower Jiao, invigorates Blood, calms the spirit
On the medial side of the lower leg, 3 cun superior to the
prominence of the medial malleolus, in the depression close to
the medial crest of the tibia
Tian Shu
(ST25)
Regulates Intestines, Spleen and Stomach, resolves damp and
damp heat, regulates Qi and Blood, eliminates stagnation
On the abdomen to 2 cun lateral to the umbilicus
Feng Long
(ST40)
Transforms phlegm and dampness, clears phlegm from the heart
and calms the spirit, activates the channel and alleviates pain
On the lower leg, midway between the tibiofemoral joint line
(level with the popliteal crease) and the lateral malleolus, two
finger- breadth later to Tiaokou ST38
Zhong Wan
(CV12)
Harmonises the middle Jiao, tonifies the Stomach and fortifies the
Spleen regulates Qi
On the midline of the abdomen, 4 cun above the umbilicus and
midway between the umbilicus and the sternocostal angle.
Qi Hai (CV6) Fosters original Qi, tonifies Qi, tonifies the Kidneys and fortifies
Yang, rescues the collapse of Yang, regulates Qi and harmonies
Blood
On the midline of abdomen, 1.5 cun inferior to the umbilicus and
3.5 cun superior to pubic symphysis
Qu Chi (LI11) Clears heat, cools Blood, eliminates wind, drains damp and
alleviates itching, regulates Qi and Blood
At the elbow, midway between Chize LU5 and the lateral
epicondyle of the humerus, at the lateral end of the transverse
cubital crease. (This point should be located with a flexed elbow.)
Yin Ling
Quan (SP9)
Regulates Spleen and resolves damp, opens and moves water
passages and benefits the lower Jiao
On the medial side of the leg, in the depression in the angle
formed by the media condyle of the of the tibia and the
posterior border of the tibia
Shui Fen
(CV9)
Regulates the water passages, harmonises the intestines and
dispels accumulations
On the midline of the abdomen, 1 cun above the umbilicus and
7 cun below the sternocostal angle
Zhong Ji
(CV3)
Regulates Qi transformation and drains damp heat, drain
dampness, benefits the uterus and regulates menstruation, dispels
stagnation and benefits the lower Jiao, fortifies the Kidney
On the midline of the lower abdomen, 4 cun inferior to the
umbilicus and 1 cun superior to the pubic symphysis
Guan Yuan
(CV4)
Fortifies original Qi and benefits essence, tonifies and nourishes
the Kidney, warms and fortifies the Spleen, benefits the uterus
and assists conception, regulates the lower Jiao
On the midline of the lower abdomen, 3 cun inferior to the
umbilicus and 2 cun superior to the public symphysis
He Gu (LI4) Activates the channel and restores the Yang On the dorsum of the hand, between the first and second
metacarpal bones, at the midpoint of the second metacarpal
bone and close to its radial border
Qi Xue (KI13) Regulates the penetrating and conception vessel, regulates the
lower Jiao
On the lower abdomen, 3 cun below the umbilicus, 2 cun
superior to the superior border of the symphysis pubis, 0.4 cun
lateral to midline (Guanyuan CV4)
Fu Liu (KI7) Benefits the Kidneys, regulates the water passages, drains damp
and clears damp heat
On the medial aspect of the lower leg, in the depression 2 cun
superior to Taixi KI3, on the anterior border of the Achilles
tendon. (KI3 is located in the depression between the tip of the
medial malleolus and the Achilles tendon)
Shui Dao
(ST28)
Warms the lower Jiao, regulates menstruation and benefits the
genital region
On the lower abdomen, 2 cun lateral to the midline and 3 cun
inferior to the umbilicus level with Guanyuan Ren 4. Note: The 2
cun line located between the midline and palpable border of the
rectus abdominis of the umbilicus.
Tai Chong
(LR3)
Spreads Liver Qi, subdues Liver Yang and extinguishes wind,
nourishes Liver Blood and Liver Yin, regulates menstruation,
regulates lower Jiao
On the dorsum of the foot, in the hollow distal to the junction of
the first and second metatarsal bones
Yang Ling
Quan (GB34)
Spreads Liver Qi and benefits the lateral costal region, clears Liver
and Gall Bladder damp heat
Below the later aspect of the knee, in the tender depression
approx. 1 cun anterior and 1 cun inferior to the head of the fibula
Acupuncture point nomenclature as per World Health Organisation guidelines for meridian alphabetic codes
aA cun is a measurement used in locating acupoints and corresponds to the distance between the two medial ends of the creases of the interphalangeal joints,
when the patient’s middle finger is flexed.
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[45]. The service is delivered by university-qualified
health coaches, including dietitians and exercise physiol-
ogists, and is available to all residents of NSW aged 16
years and above. Health coaches are trained in Health-
Change® Methodology which draws on principles and
techniques similar to those used in motivational inter-
viewing, solution-focused coaching, and cognitive behav-
ioural therapy and provides an overarching framework
for integration of these approaches into specific health
promotion programmes. HealthChange® Methodology
also integrates numerous models from evidence-based
health behaviour change literature [46]. All participants
will be referred to the GHS, and one group will be allo-
cated to receive only the GHS. The intervention consists
of a minimum of four and up to 13 individually tailored
telephone calls exploring healthy eating, physical activity,
and achieving and maintaining a healthy weight consist-
ent with national guidelines, which are also recom-
mended by international evidence-based PCOS
guidelines [4, 47]. The frequency of health coaching is
tailored according to individual need, coach and partici-
pant availability, and stage of programme, with more fre-
quent calls generally required in the early stages.
Permitted and prohibited components of treatment
Women in the body acupuncture group may be pro-
vided diet and lifestyle advice according to Chinese
medicine principles by the study acupuncturists. This
advice usually consists of recommendations to avoid
ingesting foods that are considered too “hot” or “cold”
for the patient’s constitution. However, no additional
Chinese medicine treatments will be provided including
Chinese herbal medicine or additional physical or stimu-
lation treatments such as moxibustion or cupping. Par-
ticipants will be discouraged from using other co-
interventions during the study. Any co-interventions
used are recorded at the final study visit.
Outcome measures
The primary outcomes for this study are feasibility and
acceptability of recruitment methods, intervention, and
outcome collection and will include:
a. Recruitment rates (number of enquiries and
number of enrolments per month of active
recruitment; percentage conversion to enrolment
measured as n enrolled/n of enquiries, and n
enrolled/n potentially eligible);
b. Retention rate (n completing 12-week intervention
and outcome measures/n enrolled)
c. Adherence rates (n completing at least 8 of 11
acupuncture treatments and 4 of 6 NeurovaTM
treatments; n of hours of wear of the NeurovaTM
device/percentage of women who wore the device
for the prescribed 96 h duration; n completing all
recommended phone calls with the GHS);
d. Acceptability is measured using an exit survey
which includes questions on perceived benefits of
Fig. 1 Location of ear acupuncture points
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body acupuncture, AEA, and health coaching,
perceived detriments of being in the trial, likelihood
of recommending the study to family or friends
measured on a 5 point Likert scale ranging from “I
would definitely participate/recommend it” to “I
would definitely not participate/recommend it”;
e. Credibility of the treatment and expectancy related
to treatment are collected immediately after the
first acupuncture or AEA treatment, using a
modified Credibility and Expectancy questionnaire
[48]. To maintain blinding during data analysis,
these data will be analysed after all other data have
been interpreted.
f. Safety (adverse events) which will be collected by
study acupuncturists at each treatment, or recorded
by the participant or research team at any time
during the intervention period, using an Adverse
Events Form
We will collect demographic and medical details using
a survey at baseline, including age, ethnic background,
smoking status, diet history, physical activity levels
(number of 20-min sessions of vigorous and less vigor-
ous exercise per week which will be converted to meta-
bolic equivalents), family history of type 2 diabetes,
acupuncture experience, and previous weight loss at-
tempts. Concomitant medications are recorded at the
baseline and 12-week visits.
The primary outcome for the phase IIb trial will be
change in weight in kilogrammes from baseline to end
of treatment (12 weeks). Secondary outcome measures
include other anthropometric measures, metabolic out-
comes, reproductive, psychological, quality of life, and
lifestyle habits. These are collected at baseline and at
end of treatment (12 weeks) and include the following:
Anthropometric measures
We will measure weight on a calibrated medical-grade
digital scale (Omron) with the participant in light cloth-
ing and no shoes. We will measure waist and hip cir-
cumference using medical-grade tape and height by
stadiometer at the baseline clinic visit, following proce-
dures outlined in the National Health and Nutrition
Examination Survey (NHANES) Anthropometry Proce-
dures Manual [49].
Metabolic outcomes
Glucose tolerance and insulin sensitivity are obtained
from a 2-h 75 g oral glucose and tolerance test collected
by Laverty Pathology after an overnight fast. Serum is
analysed for glucose levels using the hexokinase enzym-
atic method (ADVIA Chemistry Glucose Hexokinase_3
Concentrated Reagents (GLUH_c) enzymatic method)
and for insulin using two-site sandwich immunoassay
(ADVIA CentaurR Insulin assay, ADVIAR Chemistry
Systems, Siemens Healthcare Diagnostics, Camberley,
UK). Area under the curve (AUC) insulin will be calcu-
lated using the trapezoid method.
Reproductive outcomes
Menstrual cyclicity will be calculated from menstrual
diaries over 12 weeks. Sex hormone-binding globulin,
free testosterone and Free Androgen Index will be col-
lected by Laverty Pathology and analysed using the
ADVIA CentaurR SHBG and CentaurR Testosterone II
(TSTII) assays. Clinical hyperandrogenism is calculated
using the Ferriman-Gallwey scoring system [50].
Quality of life outcomes
We will assess both health-related and global quality of
life using the validated Modified PCOS Questionnaire
(MPCOSQ) [51] and EuroQol 5D (EQ-5D) questionnaire
[52] respectively.
Psychological outcomes
We will assess depression and anxiety symptoms using
the validated Depression Anxiety Stress Scale (DASS) 21
[53]. The construct of locus of control refers to the ex-
tent to which an individual believes that his or her envir-
onment and choices are under his or her control. This is
relevant in obesity where an external locus of control, or
the belief that events or outcomes are controlled by
forces external to oneself, is correlated with greater adi-
posity [54]. We will measure locus of control using the
validated Multidimensional Health Locus of Control
questionnaire [55].
Lifestyle habits
 Physical activity: Participants will wear an
accelerometer (Actigraph wGT3X+, initialised at 70
Hz) around the waist for 5–7 days (that includes 2
weekend days) and complete an associated sleep
diary in the week before commencing the
intervention, and in week 11
 Low eating self-efficacy, or poor confidence in one’s
ability to control eating behaviour in the presence of
challenging situations, has been identified as a po-
tential barrier to long-term adherence to reduced
energy intake. We will measure weight self-efficacy
using the validated Weight Efficacy Lifestyle Ques-
tionnaire short form [56]
 Change in dietary habits (n of daily serves of
vegetables and fruit, n of daily cups of sugar
sweetened drinks, frequency of takeaway meals or
snacks) is provided by the GHS at completion of the
study
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Autonomic outcomes
 Heart rate variability (HRV) provides non-invasive
measures of both parasympathetic (high frequency/
HF component) and sympathetic tone (low fre-
quency/LF component) [57]. HRV will be calculated
from electrocardiogram (ECG) recordings during
the clinic visits. ECG recordings take place in the
NICM Neurocognition and HEADBOX Labs at
Western Sydney University. Women will be asked to
avoid caffeine and smoking for at least 2 h prior to
HRV measurement. Five minutes of seated eyes-
closed resting-state 2-lead ECG will be recorded
with pre-jelled disposable bipolar Ag/AgCl elec-
trodes placed over the mid-sternum (medial to the
fourth intercostal space; between V1 and V2) and
fifth intercostal space at the left midaxillary line (V6)
via a Compumedics Neuroscan Synamps2 Digital
Signal Processing System and Neuroscan 4.5.1 Ac-
quire software. Data will be sampled at 1000 Hz and
amplified with the manufacturer’s default gain set-
ting. HRV will be derived from ECG trace via
MATLAB (Mathsworks®). HRV frequency bands will
be defined as very low frequency (VLF; < 0.04 Hz),
low frequency (LF; 0.04–0.15 Hz), and high fre-
quency (HF; 0.18–0.40 Hz). LF/HF ratio will also be
calculated as a measure of sympathovagal balance.
 Blood pressure is measured while sitting quietly and
after resting quietly for a few minutes, and with
both feet on the ground, using an Omron digital
automatic standard blood pressure monitor. A large
cuff is used if required. Blood pressure on both arms
will be obtained initially and the higher blood
pressure of the two will be used. Three
measurements will be taken, and the average of the
last two measurements is recorded. If there is > 10
mm/Hg or > 6mm/Hg difference in systolic or
diastolic blood pressure respectively, the participant
is asked to rest quietly for 5 min and blood pressure
measurement is repeated [58].
Criteria for success
We will consider this feasibility study a success if the fol-
lowing criteria are all met by the completion of all 12-
week follow-up visits:
 The body acupuncture, AEA interventions, and
lifestyle interventions are safe and acceptable to
participants (no serious adverse events that are
probably or definitely related to the interventions; at
least 75% of women indicate that they would
definitely or probably recommend participating in
the trial to a friend with PCOS; at least 75% of
women wore the NeurovaTM for more than 72 h at
a time)
 Recruitment is feasible (recruitment target is
reached; n of women enrolled per month of
recruitment is at least 2; percentage of women
enrolled compared to initial enquiry is greater than
12.5%; percentage of women enrolled compared to
number of women who are potentially eligible is
greater than 30%);
 Retention is satisfactory (percentage of women
completing 12-week outcome measures compared to
women enrolled is greater than 75%)
 Adherence is satisfactory in all three groups
(percentage of women completing at least 66.67% of
body acupuncture, AEA treatments or
recommended telephone calls from GHS is greater
than 75%)
 Mean credibility score is > 6 (credibility is measured
on a 9-point Likert scale)
Sample size
No sample size calculation is required as this is a feasi-
bility study. We aim to analyse 30 participants by the
end of treatment. Based on our collective experience,
where trials which have required more intensive inter-
ventions have reported a dropout rate of over 40% in
women with PCOS [59] while a randomised sham-
controlled trial on acupuncture in menopausal women
reported attrition of < 20% [60], we estimate a 25% drop-
out rate in this trial. Therefore, we aim to randomise 39
women (13 to body acupuncture, 13 to AEA, and 13 to
lifestyle alone).
Statistical analysis
Data relating to recruitment, retention, safety, adher-
ence, acceptability, and credibility are presented with de-
scriptive statistics (measures of central tendency, e.g.,
mean, variability; e.g., standard deviation; and effect size,
e.g., 95% confidence intervals). Mixed model analysis of
variance will be used to determine within-group differ-
ences for continuous outcomes between baseline and 12
weeks with time as a fixed effect and subject as a ran-
dom effect and analysis of covariance for between-group
differences for continuous outcomes with baseline score
as a covariate, time and group as fixed effects, and sub-
ject as a random effect. Intention-to-treat analysis will
be used.
Quality assurance
Point location for body acupuncture and AEA and will
be independently checked by an acupuncturist external
to the study at least once for each practitioner. We will
undertake regular calibration of digital weight scales and
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ECG equipment as per laboratory standard operating
procedures.
Safety monitoring
At each acupuncture treatment, study acupuncturists
will enquire about adverse events (AE). All participants
are provided with an AE form to complete if required
and are provided with the principal investigator’s contact
details to report all AE regardless of perceived causality.
All AEs will be assessed for causality and severity by the
chief investigator after consultation with other investiga-
tors (see Table 2) and followed up until resolution or
until such time as the event is considered stable. Serious
AE’s are reported to the Human Research Ethics Com-
mittee within 24 h of becoming known to the research
team.
Discussion
Obesity is a global health issue [61]. The worldwide
prevalence of obesity has nearly tripled between 1975
and 2014 [62]. The obesity epidemic is a major contribu-
tor to the steep rise of type 2 diabetes, cancer, and car-
diovascular disease (CVD) [63, 64]. The cost of obesity
to the global health system is estimated at US$2 trillion
annually [61]. Women with PCOS have a higher preva-
lence of being overweight or obese [3] including greater
longitudinal weight gain [65]. Overweight and obesity
worsens the features of PCOS [66], and weight manage-
ment is recommended as initial first line treatment in
international evidence-based guidelines in PCOS [4].
Women with PCOS express dissatisfaction with con-
ventional medical treatments (such as fertility drugs and
the oral contraceptive pill) and an overwhelming prefer-
ence for alternatives that they perceive to be safer [67].
They are frequent users of complementary therapies,
with up to a third using acupuncture [68]. Acupuncture
may represent a low-risk [32] non-pharmacological ad-
junct to lifestyle interventions in women with PCOS and
may contribute to reduction of the burden of chronic
disease; however, there is a paucity of evidence from
rigorous RCTs. Many RCTs fail due to inability to
recruit to target [69]. To this end, the UK Medical Re-
search Council recommends assessment of feasibility
prior to full evaluation of complex interventions [70].
This can ensure that money spent on expensive trials is
not wasted due to recruitment and retention failures.
This feasibility study will examine the safety, accept-
ability, and feasibility of recruitment and adherence to
novel adjunctive interventions for weight loss in PCOS.
Further, we will explore the impact of AEA, body acu-
puncture, and lifestyle interventions on measures of
sympathetic tone and IR, and related biomarkers that
are clinically relevant in PCOS, in order to build an ac-
curate scientific argument for the biological plausibility
of the interventions. Several sham-controlled RCTs on
acupuncture for a variety of clinical conditions suggest
that it is more efficacious than sham in reducing sympa-
thetic tone as measured by HRV [57, 71, 72]. Previous
clinical research showed that AEA resulted in improve-
ment in HRV LF/HF ratios over the course of the protocol
intervention, implying improved sympathovagal balance
[44]; however, this was measured using ambulatory HRV
monitoring, which has not been validated against the gold
standard of electrocardiogram (ECG) recordings. To date,
the effect of acupuncture on HRV in women with PCOS
has not been evaluated, although electro-acupuncture im-
proved HRV and restored oestrous cycling compared to
sham handling in a recent rat study [73].
This study also provides vital real-world feasibility data
on the acceptability of NeurovaTM device, which will
allow for further modification of the device for improved
health consumer comfort, convenience, and clinical ef-
fectiveness. This device represents an innovation in the
delivery of acupuncture, allowing the device to be used
at home, reducing the need for frequent clinic visits, and
increasing the dose of acupuncture that can be delivered.
Study findings will have the potential to generate new
understandings of the role of acupuncture and allow
greater exploration of the mechanisms underlying PCOS,
a condition of significant health burden to women, with
the potential to translate this research to other chronic
conditions that are underpinned by autonomic dysfunction.
Table 2 Assessment of causality and severity of adverse events
Assessment of causality Assessment of severity
Unrelated: where an event is not considered to be related to the study
intervention
Mild: an event that is easily tolerated by the participant, causing
minimal discomfort and not interfering with every day activities.
Possibly: although a relationship to the study intervention cannot be
completely ruled out, the nature of the event, the underlying disease,
concomitant medication or temporal relationship make other explanations
possible.
Moderate: an event that is sufficiently discomforting to interfere with
normal everyday activities.
Probably: the temporal relationship and absence of a more likely explanation
suggest the event could be related to the study intervention.
Severe: an event that prevents normal everyday activities
Definitely: The known effects of the study intervention or its physiological
mechanisms suggest that study intervention is the most likely cause.
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There are some limitations to the proposed research. It
will not be possible to blind the intervention providers or
the participants, therefore introducing the possibility of
performance bias. To minimise this risk, we will conduct
blinded outcome collection and analysis and utilise object-
ive measures for outcomes wherever possible (such as ac-
celerometers to measure physical activity levels). Further,
due to operational and funding constraints, the study is
limited to women in Sydney, and we will not be able to
test the feasibility of a multicentre trial.
Conclusion
This study addresses feasibility of a novel intervention to
treat obesity, which is a global public health concern.
With rising health costs and disease burden from obes-
ity, there is an urgent need to identify effective treat-
ments that are adjunctive to lifestyle interventions.
Should the trial methods prove to be feasible and ac-
ceptable and meet the criteria for success, we will con-
duct a phase IIb randomised controlled trial assessing
effectiveness and efficacy of the NeurovaTM device and
body acupuncture as adjuncts to lifestyle interventions
for obesity in women with PCOS.
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